MEGL vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 30, 2026

MEGL

51.8
AI Score
VS
MEGL Wins

HIVE

39.5
AI Score

Investment Advisor Scores

MEGL

52score
Recommendation
HOLD

HIVE

40score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric MEGL HIVE Winner
Forward P/E 0 62.8931 Tie
PEG Ratio 0 0 Tie
Revenue Growth 26.7% 73.5% HIVE
Earnings Growth -13.6% -99.9% MEGL
Tradestie Score 51.8/100 39.5/100 MEGL
Profit Margin -72.1% -98.5% MEGL
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY MEGL

Relative Price Performance (Last 90 Days)

MEGL 1M: -20.3% · 3M: -32.6% HIVE 1M: +9.4% · 3M: -12.0%

Current Technical Phase

MEGL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 25

RSI (14): 25.3 · Price: $0.92

HIVE

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.6%) with fading momentum, RSI 46

RSI (14): 46.5 · Price: $2.98

Fundamentals Snapshot

Metric MEGL HIVE
Market Cap — —
Forward P/E 0.0 -5.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.3% 0.7%
Gross Margin 0.7% 0.4%
Operating Margin -0.9% -0.6%
EPS -0.20 -1.39
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MEGL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.